Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The ma…
Eosinophilic Asthma
Estimated
~$10 – $8,750
Kymera Therapeutics, Inc.NCT07323654
Phase 4
Fasenra Demonstrates Durability Over the Full 8-week Treatment Period
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in p…
Eosinophilic AsthmaSevere AsthmaSevere Eosinophilic Asthma+1 more
Estimated
~$10 – $7,500
Endeavor HealthNCT07654842
Phase 3
BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist.
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS…
Eosinophilic Asthma
Estimated
~$10 – $7,500
AstraZenecaNCT06750289